IMPACT OF THIRD-LINE ZD 1839 THERAPY ON PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAD FAILED PRIOR PLATINUM AND/OR DOCETAXEL-BASED REGIMENS (ASTRA ZENECA EXPANDED ACCESS PROGRAMME)


    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.


    loading  Loading Related Articles